The androgen receptor as putative therapeutic target in hormone-refractory prostate cancer

Recent Patents on Anti-Cancer Drug Discovery

Volumn 2, Issue 3, 2007, Pages 203-211

  Kageyama, Yukio ^a,b   Hyochi, Nobuhiko ^b   Kihara, Kazunori ^b   Sugiyama, Hiroshi ^c  

^a SAITAMA CANCER CENTER   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Amplification; Androgen; Mutation; Neoplasms; Phosphorylation; Prostate; Receptor

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; ARYLBUTYRIC ACID DERIVATIVE; BETA CATENIN; BICALUTAMIDE; BOLDENONE; CYPROTERONE ACETATE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; EVEROLIMUS; GONADORELIN DERIVATIVE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE INHIBITOR; HYDROXYFLUTAMIDE; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; NILUTAMIDE; NUCLEAR RECEPTOR COACTIVATOR 2; RAF PROTEIN; RAS PROTEIN; STEROID 5ALPHA REDUCTASE; STEROID RECEPTOR COACTIVATOR 1; TEMSIROLIMUS; UNINDEXED DRUG; VORINOSTAT;

ADVANCED CANCER; ARTICLE; CANCER CELL; CANCER GROWTH; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; DRUG SYNTHESIS; DRUG WITHDRAWAL; GENE MUTATION; HUMAN; MALE; MICROENVIRONMENT; NONHUMAN; PATENT; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RECURRENT CANCER; SIGNAL TRANSDUCTION; SOLID TUMOR; WITHDRAWAL SYNDROME;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PATENTS AS TOPIC; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 36749040462     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489207782497172     Document Type: Article

References (117)

1. Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm. J Clin Oncol 1997; 15: 382-86.
2. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prcdnisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12.
3. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prcdnisonc for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20.
4. De Vere White R, Meyers F, Chi SG, et al. Human androgen receptor expression in prostate cancer following androgen ablation. Eur Urol 1997; 31:1-6.
5. Ruizeveld De Winter JA, Trapman J, et al. Androgen receptor expression in human tissues: An immunohistochemical study. J Histochem Cytochem 1991; 39: 927-36.
6. Huggins CB, Hodges CV. Studies on prostatic cancer. 1. The effect of castration, of estrogen and of androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-97.
7. Huggins C. Endocrine-induced regression of cancers. Cancer Res 1967; 27: 1925-30.
8. Taplin ME, Balk SP. Androgen Receptor: A key molecule in the progression of prostate cancer to hormone independence. J Cell Biochein 2004; 91: 483-90.
9. Suzuki H, Ueda T, Ichikawa T, Ito H. Androgen receptor involvement in the progression of prostate cancer. Endocrine-Related Cancer 2003; 10: 209-16.
10. Evans RM. The steroid and thyroid hormone receptor super family. Science 1988; 240: 889-95.
11. Edwards J, Bartlett JMS. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: modifications to the androgen receptor. BJU Int 2005; 95:1320-26.
12. Lee HJ, Chang C. Recent advances in androgen receptor action. Cellular Mol Life Sci 2003; 60: 1613-22.
13. Zhu Z, Becklin RR, Desiderio DM, Dalton JT. Identification of a novel phosphorylation site in human androgen receptor by mass spectrometry. Biochem Biophys Res Commun 2001; 284: 836-44.
14. Moras D, Gronerneyer H. The nuclear receptor ligand-binding domain: structure and function, Curr Opin Cell Biol 1998; 10: 384-91.
15. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002; 20: 3001-15.
16. Feldman BJ, Feldman D. The development of androgen-indcpcndent prostate cancer. Nat Rev Cancer 2001; 1: 34-45.
17. Brinkmann AO, Faber PW, Van Roou CJ et al. The human androgen receptor: Domain structure, genomic organization, and regulation of expression. J Steroid Biochem 1989; 34: 307-10.
18. Faber PW, Kuiper GG, van Rooij HC, van der Korput JA, Brinkmann AO, Trapman J. The N terminal domain of the human androgen receptor is encoded by one, large exon. Mol Cell Endocrinol 1989; 61: 257-62.
19. Irvine RA, Yu MC, Ross RY, Coctzcc GA. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995; 55: 1937-40.
20. Giovannucci E, Stampfer MJ, Krithivas Y, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997; 94: 3320-23.
21. Correa-Cerro L, Wohr G, Haussler J, et al. (CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population. Eur J Hum Genet 1999; 7: 357-62.
22. Janne OA, Moilanen AM, Poukka H, et al. Androgen receptor-interacting nuclear proteins. Biochem Soc Trans 2000; 28: 401-405.
23. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases:lessons from a rapid autopsy program. Cancer Res 2004; 64: 9209-16.
24. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003; 349: 366-81.
25. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004; 351: 1488-90.
26. Tindall D, Horne FM, Hruszkcwycz A, et al. Symposium on androgen action in prostate cancer. Cancer Res 2004; 64: 7178-80.
27. Chen CD, Welsie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-39.
28. Kokontis J, Takakura Y, Hay N, Liao S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 1994; 54: 1566-73.
29. Kokontis JM, Hay N, Liao S. Progression of LNCaP prostate tumor cells during androgen deprivation: Hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 1998; 12: 941-53.
30. Umekita Y, Hiipakka RA, Kokontis JM, Liao S. Human prostate tumor growth in athymic mice: Inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci USA 1996; 93: 11802-807.
31. Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9: 401-406.
32. Koivisto P, Korionen J, Palmberg C, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57: 314-19.
33. Linja MJ, Savinainen KJ, Saramaki OR, et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001; 61: 3550-55.
34. Latil A, Bieche I, Vidaud D, et al. Evaluation of androgen, estrogen (ER α and ER β, and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 2001; 61: 1919-26.
35. Gregory CW, Johnson RT Jr., Mohler JL, et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001; 61: 2892-98.
36. Labrie F, Dupont A, Belanger A, et al. Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocr Rev 1986; 7: 67-74.
37. Holzeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004; 164: 217-27.
38. Makridakis N, Ross RK, Pike MC, et al. A prevalent missense substitution that modulates activity of prostatic steroid 5-alpha reductase. Cancer Res 1997; 57: 1020-22.
39. Wilding G, Chen M, Gelmann EP. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 1989; 14: 103-15.
40. Veldscholte J, Berrevoets CA, Ris-Stalpers C, et al. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 1992; 41: 665-69.
41. Zhao XY, Malloy PJ, Krishnan AV, et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 2000; 6: 703-706.
42. Buchanan G, Greenberg NM, Scher HI, et al. Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 2001; 7: 1273-81.
43. Shi XB, Ma AH, Xia L, et al. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res 2002; 62: 1496-502.
44. Taplin ME, Buley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332:1393-98.
45. Tilley WD, Buchanan G, Hickey TE, et al. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996; 2: 277-85.
46. Marcelli M, Ittmann M, Mariani S, et al. Androgen receptor mutations in prostate cancer. Cancer Res 2000; 60: 944-49.
47. Taplin ME, Rajeshkumar B, Halabi S, et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003; 21: 2673-78.
48. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 1566-72.
49. Small EJ, Srinivas S. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer (Phila) 1995; 76: 1428-34.
50. Veldscholte J, Ris-Stalpers C, Kuiper GG, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Common 1990; 173: 534-40.
51. Veldscholte J. Berrevoets CA, Brinkmann AO, Grootegoed JA, Mulder E. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation, Biochemistry 1992; 31: 2393-99.
52. Fenton MA, Shuster TD, Fertig AM, et al. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 1997; 3: 1383-88.
53. Hara T, Miyazaki J, Araki H, et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003; 63: 149-53.
54. Yoshida T, Kinoshita H, Segawa T, et al. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res 2005; 65; 9611-16.
55. Culig Z, Hobisch A, Cronauer MV, et al. Mutant androgen receptor detected in anadvanced stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 1993; 7: 1541-50.
56. Culig Z, Hobiscb A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994; 54: 5474-78.
57. Culig Z, Steiner H, Bartsch G, et al. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 2005; 95: 497-505.
58. Shariat S, Andrews B, Kattan M, Wheeler KJ, Slawin K. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001; 58: 1008-15.
59. Craft N, Shostak Y, Carey M, et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999; 5: 280-85.
60. Rochette-Egly C. Nuclear receptors. Integration of multiple signaling pathways through phosphorylation. Cell Signal 2003; 15: 355-66.
61. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 2003; 63: 1981-89.
62. Weber MJ, Gioeli D. Ras signaling in prostate cancer progression. J Cellular Biochem 2004; 91: 13-25.
63. Gioeli D, Mandell JW, Petrom GR, Frierson HF, Weber MJ. Activation of mitogen-activated protein kinasc associated with prostate cancer progression. Cancer Res 1999; 59: 279-84.
64. Ghosh PM, Malik S, Bedolla R, Kreisberg JI. Akt in prostate cancer: Possible role in androgen-independence. Current Drug Metabolism 2003; 4: 487-96.
65. Gao N, Zhang Z, Jiang BH, Shi XL. Role of P13K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Common 2003; 310: 1124-32.
66. Murillo H, Huang HJ, Schmidt LJ, Smith DI, Tindall DJ. Role of P13K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001; 142: 4795-805.
67. Kimbro KS, Simons JW. Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer 2006; 13: 739-49.
68. Saramaki OR, Savinainen KJ, Nupponen NN, Bratt O, Visakorpi T. Amplification of hypoxia-inducible factor 1alpha gene in prostate cancer. Cancer Genet Cytogenet 2001; 128: 31-34.
69. Horii K, Suzuki Y, Kondo Y, et al. Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells. Mol Cancer Res 2007; 5: 383-91.
70. Gregory CW, He B, Johnson RT, et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001; 61: 4315-19.
71. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23: 8253-61.
72. Edwards J, Bartlett JMS. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways. BJU Int 2005; 95: 1327-35.
73. Rahman M, Miyamoto H, Chang C. Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications. Clin Cancer Res 2004; 10: 2208-19.
74. Dotzlaw H, Moehren U, Mink S, Cato AC, Iñiguez Lluhí JA, Baniahmad A. The amino terminus of the human AR is target for corepressor action and antihormone agonism. Mol Endocrinol 2002; 16: 661-73.
75. Berrevoets CA, Umar A, Trapman J, et al. Differential modulation of androgen receptor transcriptional activity by the nuclear receptor corepressor (N-CoR). Biochem J 2004; 379: 731-38.
76. Hodgson MC, Astapova I, Cheng S, et al. The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J Biol Chem 2005; 280: 6511-19.
77. Li P, Yu X, Ge K, et al. Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. Am J Pathol 2002; 161: 1467-74.
78. Wang L, Hsu CL, Chang C. Androgen receptor corepressors: an overview. Prostate 2005; 63: 117-30.
79. Urushibara M, Ishioka J, Hyochi N, et al. Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors. Prostate 2007; 67:799-807.
80. Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino,17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005; 23: 4152-61.
81. Grem JL, Morrison G, Guo XD, et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxy-geldanamycin in adult patients with solid tumors. J Clin Oncol 2005; 23: 1885-93.
82. Goetz MP, Toft D, Reid J, et al. Phase I trial of 7-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005; 23: 1078-87.
83. Ramanathan RK, Trump DL, Eiseman JL, et al. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG,NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res. 2005; 11: 3385-91.
84. Butler LM, Agus DB, Scher HI, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000; 60: 5165-70.
85. Chen L, Meng S, Wang H, et al. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther 2005; 4: 1311-19.
86. Carducci MA, Gilbert J, Bowling MK, et al. A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 2001; 7: 3047-55.
87. Kelly WK, Richon VM, O'Connor O, et al. Phase I clinical trial of histone deactylase inhibitor: suberylanilide hydroxamic acid (SAHA) administered intravenously. Clin Cancer Res 2003; 9: 3578-88.
88. Eder IE, Culig Z, Ramoner R, et al. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther 2000; 7: 997-1007.
89. Chang CY, Abdo J, Hartney T, et al. Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display. Mol Endocrinol 2005; 19: 2478-90.
90. Papatsoris AG, Karamouzis MV, Papavassiliou AG. The power and promise of "rewiring" the mitogen-activated protein kinase network in prostate cancer therapeutics. Mol Cancer Ther 2007;6:811-19.
91. Pommery N, Henichart JP. Involvement of P13K/Akt pathway in prostate cancer-potential strategies for developing targeted therapies. Mini Rev Med Chem 2005; 5: 1125-32.
92. Fu Z, Smith PC, Zhang LZ et al. Effects of Raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst 2003; 95: 878-89.
93. Boddy JL, Fox SB, Han C, et al. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1alpha, HIF-2alpha, and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res 2005; 11: 7658-63.
94. Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H, Simons JW. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 2003; 9: 2416-25.
95. Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006; 13: S125-35.
96. Solit DB, Scher HI, Rosen N. Hsp90 as a therapeutic target in prostate cancer. Semin Oncol 2003; 30: 709-16.
97. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic, and HIF-1-dependent pathways. Nat Med 2004; 10: 594-601.
98. Mousses S, Wagner U, Chen Y, et al. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene 2001; 20: 6718-23.
99. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 2004; 91: 1420-24.
100. Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005; 65: 2825-31.
101. Hanson, R.N., Friel, C., Lee, C.Y.: US20067041839 (2006).
102. Hanson, R.N., Friel, C., Lee, C.Y.: US20060148773A1 (2006).
103. Scanlan, T.S., Kadnikov, D.V.: US20070049629A1 (2007).
104. Scanlan, T.S., Kadnikov, D.V.: WO07025303A2 (2007).
105. Danso-Danquah, R., Abraham, D.J., Lin, H.-Ru., Burnett, J.C.: US20060287359A1 (2006).
106. Loren, J.C., Miller, T., Pedram, B., Rowley, C.V., Shen, Y., Van, O.C.A., Zhi, L.: WO07005887A2 (2007).
107. Gurova, K., Gudkov, A.: WO07041497A2 (2007).
108. Balog, J.A., Salvati, M.E., Fink, B.E.: US20070088039A1 (2007).
109. Meissner, R.S., Perkins, J.J.: US20060241107A1 (2006).
110. Coleman, P.J., Neilson, L.A.: US20077196076 (2007).
111. Chang, C.: US20067052908 (2006).
112. Chang, C.: US20060270591A1 (2006).
113. Sawyers, C.L., Jung, M.E., Chen, C.D., Ouk, S., Welsbie, D., Tran, C., Wongvipat, J., Yoo, D.: US20070004753A1 (2007).
114. Sawyers, C.L., Jung, M.E., Chen, C.D., Ouk, S., Welsbie, D., Tran, C., Wongvipat, J., Yoo, D.: WO06124118A1 (2006).
115. Fletterick, R., Estebanez-Perpina, E., Hur, E., Pfaff, S.J., Buehrer, B.M.: US20070087352A9 (2007).
116. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001; 93: 1687-97.
117. Reddy GP, Barrack ER, Dou QP, et al. Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer. J Cell Biochem 2006; 98: 1408-23.